Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Clinical evidence

V-0046

30 evidence topics · 6 sources

Objective
Location and study date
Registered study dates, sponsor, and sites
FieldQuoted record
Study start“2005-04”
Primary completion (estimated)“2008-10”
Study completion (estimated)“2010-09”
Number of sites“This study has 10 locations”
Study design
Registered design details
Eligibility criteria
Treatment
Study outcomes
Rationale for using maximum tolerated dose as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Registered enrollment
FieldQuoted record
Enrollment (estimated)“75”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Complete response at 3 months by schedule: company presentation
ScheduleComplete response at 3 months
Single dose“3/13 (23%)”
Every 28 days“6/13 (46%)”
Weekly × 6“7/9 (78%)”
Multi-dose (every 28 days and weekly × 6)“13/22 (59%)”
Total“16/35 (46%)”
Complete response at 3 months by dose: company presentation
DoseComplete response at 3 months
1 × 10^12 viral particles“8/13 (62%)”
3 × 10^12 viral particles“4/9 (44%)”
1 × 10^13 viral particles“4/10 (40%)”
3 × 10^13 viral particles“0/3 (0%)”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary: limitations of V-0046
  • Design: V-0046 was a phase 1, open-label, non-randomized dose-escalation study in 35 participants, with cohorts of three to six participants at each dose and schedule, so efficacy estimates rest on small subgroups (for example, 9 participants on the weekly × 6 schedule).
  • Population: eligibility required failure of at least one prior BCG treatment and allowed G2 disease, which differs from the BCG-unresponsive definition used in BOND-003.
  • Reported results differ by source: the 2012 publication reports a complete response rate of 48.6% with a median duration of 10.4 months, a 2010 congress report gives 46%, and a 2023 company presentation gives 16 of 35 participants (46%) at 3 months with a median duration of 8.4 months. The multi-dose complete response rate is 63.6% (14 of 22) in the publication and 13 of 22 (59%) in the presentation.
  • The association between retinoblastoma phosphorylation and response (81.8%, 9 of 11) comes from an exploratory, retrospective assessment of a subset of 18 participants.
  • The registry record lists an estimated primary completion in October 2008 and an estimated enrollment of 75 participants, against 35 participants treated.
  • Only the abstract of the 2012 publication is openly available.